StreetInsider.com News Articles

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Tue, 23 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26679353.html

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Tue, 23 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26679353.html

Silexion gets German approval for pancreatic cancer trial of SIL204

Tue, 23 Jun 2026 08:40:23 -0400

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced it has received approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM) to initiate a Phase 2/3 clinical trial of its lead drug candidate SIL204 in patients with locally advanced pancreatic cancer.

The approval was granted without conditions under EU Regulation No. 536/2014, with Germany serving as the Reporting Member State. The Ethics Committee of the North Rhine Medical Association also issued a positive opinion on the trial's conduct in Germany.

The German clearance follows an April 2026 Clinical Trial Application submission and builds on a March 2026 approval from the Israeli Ministry of

Silexion gets German approval for pancreatic cancer trial of SIL204

Tue, 23 Jun 2026 08:40:23 -0400

The German clearance follows an April 2026 Clinical Trial Application submission and builds on a March 2026 approval from the Israeli Ministry of

Silexion gets German approval for pancreatic cancer trial of SIL204

Tue, 23 Jun 2026 08:40:23 -0400

The German clearance follows an April 2026 Clinical Trial Application submission and builds on a March 2026 approval from the Israeli Ministry of

Silexion gets German approval for pancreatic cancer trial of SIL204

Tue, 23 Jun 2026 08:40:23 -0400

The German clearance follows an April 2026 Clinical Trial Application submission and builds on a March 2026 approval from the Israeli Ministry of

Silexion gets German approval to begin Phase 2/3 pancreatic cancer trial

Tue, 23 Jun 2026 08:40:14 -0400

The approval was granted without conditions under EU Regulation No. 536/2014 and the German Medicines Act, with Germany serving as the Reporting Member State under the EU Clinical Trials Regulation. The Ethics Committee of the North Rhine Medical Association also issued a positive opinion for the trial's conduct in Germany.

The German clearance follows an approval from the Israeli Ministry of

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Tue, 23 Jun 2026 08:40:00 -0400

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries

First patient dosing expected in the coming weeks at one of the activated Israeli or

Form EFFECT Silexion Therapeutics

Mon, 22 Jun 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260622/26669358.html

Form EFFECT Silexion Therapeutics

Mon, 22 Jun 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260622/26669358.html

Form 424B3 Silexion Therapeutics

Thu, 18 Jun 2026 09:37:00 -0400
si-local-file:///var/storage/secattach/20260618/26663950.html

Form 424B3 Silexion Therapeutics

Thu, 18 Jun 2026 09:37:00 -0400
si-local-file:///var/storage/secattach/20260618/26663950.html

Form DEF 14A Silexion Therapeutics For: Jun 16

Tue, 16 Jun 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260616/26654809.html

Form DEF 14A Silexion Therapeutics For: Jun 16

Tue, 16 Jun 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260616/26654809.html

Form S-3 Silexion Therapeutics

Fri, 12 Jun 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260612/26640722.html

Form S-3 Silexion Therapeutics

Fri, 12 Jun 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260612/26640722.html